Neurology:应用他汀类药物可降低卒中后出血的风险

2016-04-09 MedSci MedSci原创

目标:评估急性缺血性卒中(AIS)发生前后应用他汀类药物治疗对急性脑出血(ICH)的风险,急性后期ICH的风险及90天死亡率的影响。方法:研究者从虚拟国际卒中试验档案(VISTA)这一国际资料库的临床试验数据中选取数据。应用倾向评分匹配,研究者回顾性比较先前应用他汀治疗的患者和AIS后3天开始应用他汀类治疗的患者。主要预后为急性症状型ICH(sICH),任何急性ICH,急性后期ICH和随访3个月的

目标:评估急性缺血性卒中(AIS)发生前后应用他汀类药物治疗对急性脑出血(ICH)的风险,急性后期ICH的风险及90天死亡率的影响。

方法:研究者从虚拟国际卒中试验档案(VISTA)这一国际资料库的临床试验数据中选取数据。应用倾向评分匹配,研究者回顾性比较先前应用他汀治疗的患者和AIS后3天开始应用他汀类治疗的患者。主要预后为急性症状型ICH(sICH),任何急性ICH,急性后期ICH和随访3个月的死亡率。

结果:共纳入有8535例患者(平均年龄70岁,54%为男性,基线NIHSS评分13)。倾向评分匹配后,先前进行他汀治疗的患者与sICH(校正OR 1.33,95% CI 0.83-2.14)或任何ICH(OR 1.35,95% CI 0.92-1.98)并不存在强相关。没有证据显示先前应用他汀类治疗与溶栓之间存在相互作用。AIS后服用他汀类药物与急性后期ICH不相关(校正HR 1.60,95% CI 0.70-3.65)。先前应用他汀类药物的患者90天死亡率降低(校正HR 0.84,95% CI 0.70-1.00),尤其是AIS后应用他汀类药物治疗的患者(校正HR 0.67,95% CI 0.46-0.97)。

结论:不管是否进行溶栓治疗,AIS前应用他汀类药物治疗与早期出血并发症不相关。AIS后早期应用他汀类药物治疗不影响急性后期ICH的风险,但是可能与死亡率下降相关。

原文出处:

Scheitz JF, MacIsaac RL, et al. Statins and risk of poststroke hemorrhagic complications. Neurology. 2016 Mar 25.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999673, encodeId=8a3a19996e3eb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 12 13:08:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044404, encodeId=9aee2044404a0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Aug 16 14:08:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671238, encodeId=fcb516e1238ae, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Nov 15 09:08:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78119, encodeId=01d8e811975, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78120, encodeId=4761e8120b4, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-12 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999673, encodeId=8a3a19996e3eb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 12 13:08:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044404, encodeId=9aee2044404a0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Aug 16 14:08:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671238, encodeId=fcb516e1238ae, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Nov 15 09:08:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78119, encodeId=01d8e811975, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78120, encodeId=4761e8120b4, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999673, encodeId=8a3a19996e3eb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 12 13:08:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044404, encodeId=9aee2044404a0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Aug 16 14:08:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671238, encodeId=fcb516e1238ae, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Nov 15 09:08:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78119, encodeId=01d8e811975, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78120, encodeId=4761e8120b4, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999673, encodeId=8a3a19996e3eb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 12 13:08:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044404, encodeId=9aee2044404a0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Aug 16 14:08:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671238, encodeId=fcb516e1238ae, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Nov 15 09:08:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78119, encodeId=01d8e811975, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78120, encodeId=4761e8120b4, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1999673, encodeId=8a3a19996e3eb, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 12 13:08:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044404, encodeId=9aee2044404a0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Aug 16 14:08:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671238, encodeId=fcb516e1238ae, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Nov 15 09:08:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78119, encodeId=01d8e811975, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78120, encodeId=4761e8120b4, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

相关威廉亚洲官网

血脂血压正常的人群应否接受他汀与降压治疗?——关注HOPE-3研究结论

作者:河北省人民医院  郭艺芳 刚刚在ACC年会上揭晓了HOPE-3研究结果,表明无心血管疾病的中等风险水平的人群降压治疗无益,但他汀治疗可显著降低主要终点事件发生率。近年来,关于不同心血管危险水平人群的降压目标值一直是国内外学者广泛关注的热点。自2013年以来,欧美国家颁布的多部威廉亚洲博彩公司 性文件均不同程度的放宽了高危人群的血压控制目标。然而在刚过去的2015年度,SPRINT研

NEJM:他汀类药物可显著降低中度危险人群的心血管疾病风险

先前的试验表明,使用他汀类药物降低胆固醇可减少无心血管疾病人群的心血管事件风险。这些试验主要包括胆固醇或炎性标志物升高的人群,主要是白人。但他汀类的益处是否可以延伸到无心血管疾病的中度危险人群,不同种族人群尚不清楚。

Lancet:他汀药物相关性免疫介导坏死性肌病-案例报道

2013年12月,59岁男性因加重的骨盆带肌痛和近端下肢无力无法行走就诊神经科。肌痛开始于2012年3月,也就是服用阿托伐他汀4个月后,一直服用他汀直到2013年9月。查体发现该患者有严重的近端下肢轻瘫。辅助检查提示血清肌酸激酶浓度3453 U/L(正常应该<171 U/L),但是没有系统性炎症表现。肌电图提示广泛的急性肌痛变化。T1相骨盆MRI提示广泛的肌肉萎缩。右侧臀大肌组织活检提示坏死

BMJ Open:他汀对血脂异常发生率似乎没什么卵用

血脂异常是心血管疾病主要危险因素,而心血管疾病又是全球范围内主要死亡原因。研究者进行了一项横断面研究,探究初级医疗保健机构加拿大人群中血脂异常发生情况。该研究共纳入了134074名>20岁非妊娠成年人,通过加拿大威廉亚洲博彩公司 识别血脂异常,使用多因素回顾分析比较血脂异常情况。研究数据显示,纳入人群平均年龄59.2岁,其中55.8%是女性。34.8%的参与者没有血脂异常,有1种、2种、3种血脂异常的参与者分别

Circulation: 应用他汀药物后,血脂和冠心病发生风险之间的相关性减弱

背景:2001年胆固醇治疗威廉亚洲博彩公司 发表后,US冠心病成人中他汀类药物的应用增加。方法:研究者收集REGARDS研究中的9578名受试者及KPSC中346 595人,2003年到2007年间的血脂水平,评估血脂和CHD之间的相关性。研究者也收集了1987到1989 ARIC研究中14 590名受试者的血脂水平,对其进行相同的分析。分析限制在45到64岁间,没有CHD,也没有服用他汀类药物的黑人和白人。基

Eur J Clin Pharmacol:卒中前,应用他汀类药物可降低卒中的严重程度

背景:卒中是一个重要的健康问题,发病率和死亡率较高。各种危险因素和心血管药物治疗组影响卒中的发生率,但是药物应用和卒中的严重程度之间的关系尚不清楚。目标:确定卒中前心血管药物使用是否与卒中严重程度相关。方法:回顾性分析布一个数据库中的数据,1974名在鲁塞尔UZ总医院住院的疑似卒中患者。应用NHISS分数评估卒中的严重程度。第一,多变量线性回归模型包括心血管药物组。第二,获得临床可以解释的结果,所